GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Rekah Pharmaceutical Prod Ltd (XTAE:REKA) » Definitions » Asset Turnover

Rekah Pharmaceutical Prod (XTAE:REKA) Asset Turnover : 0.19 (As of Sep. 2024)


View and export this data going back to 2002. Start your Free Trial

What is Rekah Pharmaceutical Prod Asset Turnover?

Asset Turnover measures how quickly a company turns over its asset through sales. It is calculated as Revenue divided by Total Assets. Rekah Pharmaceutical Prod's Revenue for the three months ended in Sep. 2024 was ₪87.2 Mil. Rekah Pharmaceutical Prod's Total Assets for the quarter that ended in Sep. 2024 was ₪453.1 Mil. Therefore, Rekah Pharmaceutical Prod's Asset Turnover for the quarter that ended in Sep. 2024 was 0.19.

Asset Turnover is linked to ROE % through Du Pont Formula. Rekah Pharmaceutical Prod's annualized ROE % for the quarter that ended in Sep. 2024 was -11.21%. It is also linked to ROA % through Du Pont Formula. Rekah Pharmaceutical Prod's annualized ROA % for the quarter that ended in Sep. 2024 was -4.13%.


Rekah Pharmaceutical Prod Asset Turnover Historical Data

The historical data trend for Rekah Pharmaceutical Prod's Asset Turnover can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Rekah Pharmaceutical Prod Asset Turnover Chart

Rekah Pharmaceutical Prod Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Asset Turnover
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.59 0.68 0.62 0.66 0.69

Rekah Pharmaceutical Prod Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Asset Turnover Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.17 0.18 0.19 0.15 0.19

Competitive Comparison of Rekah Pharmaceutical Prod's Asset Turnover

For the Drug Manufacturers - Specialty & Generic subindustry, Rekah Pharmaceutical Prod's Asset Turnover, along with its competitors' market caps and Asset Turnover data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Rekah Pharmaceutical Prod's Asset Turnover Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Rekah Pharmaceutical Prod's Asset Turnover distribution charts can be found below:

* The bar in red indicates where Rekah Pharmaceutical Prod's Asset Turnover falls into.


;
;

Rekah Pharmaceutical Prod Asset Turnover Calculation

Asset Turnover measures how quickly a company turns over its asset through sales.

Rekah Pharmaceutical Prod's Asset Turnover for the fiscal year that ended in Dec. 2023 is calculated as

Asset Turnover
=Revenue/Average Total Assets
=Revenue (A: Dec. 2023 )/( (Total Assets (A: Dec. 2022 )+Total Assets (A: Dec. 2023 ))/ count )
=321.663/( (448.418+484.721)/ 2 )
=321.663/466.5695
=0.69

Rekah Pharmaceutical Prod's Asset Turnover for the quarter that ended in Sep. 2024 is calculated as

Asset Turnover
=Revenue/Average Total Assets
=Revenue (Q: Sep. 2024 )/( (Total Assets (Q: Jun. 2024 )+Total Assets (Q: Sep. 2024 ))/ count )
=87.19/( (451.832+454.357)/ 2 )
=87.19/453.0945
=0.19

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Companies with low profit margins tend to have high Asset Turnover, while those with high profit margins have low Asset Turnover. Companies in the retail industry tend to have a very high turnover ratio.


Rekah Pharmaceutical Prod  (XTAE:REKA) Asset Turnover Explanation

Asset Turnover is linked to ROE % through Du Pont Formula.

Rekah Pharmaceutical Prod's annulized ROE % for the quarter that ended in Sep. 2024 is

ROE %**(Q: Sep. 2024 )
=Net Income/Total Stockholders Equity
=-18.692/166.7145
=(Net Income / Revenue)*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(-18.692 / 348.76)*(348.76 / 453.0945)*(453.0945/ 166.7145)
=Net Margin %*Asset Turnover*Equity Multiplier
=-5.36 %*0.7697*2.7178
=ROA %*Equity Multiplier
=-4.13 %*2.7178
=-11.21 %

Note: The Net Income data used here is four times the quarterly (Sep. 2024) net income data. The Revenue data used here is four times the quarterly (Sep. 2024) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** The ROE % used above is for Du Pont Analysis only. It is different from the defined ROE % page on our website, as here it uses Net Income instead of Net Income attributable to Common Stockholders in the calculation.

It is also linked to ROA % through Du Pont Formula:

Rekah Pharmaceutical Prod's annulized ROA % for the quarter that ended in Sep. 2024 is

ROA %(Q: Sep. 2024 )
=Net Income/Total Assets
=-18.692/453.0945
=(Net Income / Revenue)*(Revenue / Total Assets)
=(-18.692 / 348.76)*(348.76 / 453.0945)
=Net Margin %*Asset Turnover
=-5.36 %*0.7697
=-4.13 %

Note: The Net Income data used here is four times the quarterly (Sep. 2024) net income data. The Revenue data used here is four times the quarterly (Sep. 2024) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Therefore, it is a good sign if a company's Asset Turnover is consistent or even increases. If a company's asset grows faster than sales, its Asset Turnover will decline, which can be a warning sign.


Rekah Pharmaceutical Prod Asset Turnover Related Terms

Thank you for viewing the detailed overview of Rekah Pharmaceutical Prod's Asset Turnover provided by GuruFocus.com. Please click on the following links to see related term pages.


Rekah Pharmaceutical Prod Business Description

Traded in Other Exchanges
N/A
Address
30 Hamelacha Street, Holon, ISR
Rekah Pharmaceutical Prod Ltd is engaged in the manufacturing, importing, marketing, and distribution of pharmaceuticals and cosmetics. It primarily caters to the needs of hospitals, retirement homes, and national medical healthcare services.

Rekah Pharmaceutical Prod Headlines

No Headlines